Andy Chen
Catalyst Preview: INSM Ph3 ASPEN in Bronchiectasis
Andy Chen | Our scenario analysis of the upcoming INSM catalyst (ASPEN Ph3 in late-Q2 2024) as well as a deep-dive on brensocatib and ASPEN’s trial design.
Truman Patterson
FLASH: D. R. HORTON, INC. (DHI): DHI: 2Q24 Conference Call Takeaways
Truman Patterson
D.R. Horton, Inc. (DHI) Model
Truman Patterson